# Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Source: https://onco.cc/trials/nct06168786/  
OnCo record `nct06168786` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib and cadonilimab in colorectal cancer, run by Huazhong University of Science and Technology, now recruiting.

## Summary

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC is a phase 2, interventional study registered as NCT06168786 by Huazhong University of Science and Technology, with a registry enrolment figure of 40 participants, started 2023-06-20 and due to reach its primary completion in 2026-02-28. Interventions recorded: Fruquintinib; Cadonilimab; SBRT. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06168786
- Phase: 2
- Setting: A Phase II, Single-arm, Open-label, Multi-Centers Study of Cadonilimab Combined With Fruquintinib and SBRT as A Third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer
- Sponsor: Huazhong University of Science and Technology
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06168786: https://clinicaltrials.gov/study/NCT06168786

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06168786.json